Hoechst Roussel Pharmaceuticals

Hoechst Marion Roussel

Aventis Pharmaceuticals Inc.

Sanofi

Aventis Hoklings Inc.

Hoescht Roussel Pharmaceuticals Inc.

Brian S Freed

Gregory H Merriman

Barbara S Rauckman

John J Tegeler

R Richard Hamer

Russell R Hamer

John D Tomer, Iv

Gregory M Shutske

Richard C Allen

Richard C Effland

Larry A Davis

Joseph T Klein

Gordon E Olsen

Russell R Harner

Edward J Glamkowski

Grover C Helsley

Nicholas J Hrib

Lawrence L Martin

Raymond W Kosley, Jr

Barbara E Kurys

David Fink

George Lee

John I White

Russell R Harmer

Yulin Chiang

John G Jurcak

David R Borcherding

David M Fink

Martin Smrcina

Alexandre Gross

Tieu-Binh Le

Brian L Pedgrift

James Hendrix

Gregory Shutske

Patrick Shum

Reda Hanna

Gerard Charles Rosse

Stanly John

David Squire Thorpe

Russell Richard Lee Hamer

Russell R Hanner

Nicole Willard

Thomas Joseph Caulfield

Jennifer Williford Clemens

Robert S Francis

Antonio Daniel Ramos

William Shelly Wire

Jianhong Zhao

The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

Substituted benzoylamino-indan-2-carboxylic acids and related compounds

The present invention provides compounds of Formula (I) and ester prodrugs, pharmaceutically acceptable salts or solvates of such compounds; or ester prodrugs of such salts or solvates; pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF).

Pyrazoles as inhibitors of tumor necrosis factor

The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as Dantagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of Dreceptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

[object Object]

The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as Dantagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of Dreceptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

Novel 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols, intermediates and processes for the preparation thereof, and methods of reducing inflammation and cell proliferation, and relieving memory dysfunction, and inhibiting bacterial and fungal growth are disclosed.

1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino 1,3-propanediols and related compounds

Novel N-(pyridinylamino)isoindolines and related compounds, intermediates and processes for the preparation thereof, and methods of relieving memory dysfunction and treating depression utilizing the N-(pyridinylamino)isoindolines and related compounds, the intermediates or compositions thereof are disclosed.

N-(pyridinylamino) isoindolines and related compounds

1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino- 1,3-propanediols and

This invention relates to N-hydroxy-dibenz�b,e!oxepinalkylamines, N-hydroxy-dibenz�b,e!oxepinalkanoic acid amides and related heterocyclic analogues of the formula ##STR1## where X together with the carbon atoms to which it is attached forms a benzene or thiophene ring; W and Z are independently hydrogen, halogen, loweralkyl, or trifluoromethyl; R.sup.1 is hydrogen, arylloweralkyl, loweralkoxycarbonyl, loweralkylcarbonyl, arylcarbonyl or arylloweralkylcarbonyl; R.sup.2 is loweralkyl, cycloalkyl, arylloweralkyl, loweralkoxycarbonyl, loweralkylcarbonyl, arylcarbonyl or arylloweralkylcarbonyl; m is 0 or 1 and n is an integer of 0 to 4 or the pharmaceutically acceptable salts thereof. The compounds of this invention are useful as analgesics and topical antiinflammatory agents for the treatment of various dermatoses and agents for the treatment of conditions where accumulation of cyclooxygenase and/or lipoxygenase metabolites is a causative factor.

N-hydroxy-dibenz�b,e!oxepinalkylamines,

N-hydroxy-dibenz �b,e!oxepinalkylamines, N-hydroxy-dibenz

Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.

Aminoalkyloximers

Aminoalkyloximes

Aminoalkyloximes for treating depression and affective disorders

Growing community of inventors

Phillipsburg, NJ, United States of America

Brian S Freed